Common Vaccine Offers Hope Against Aggressive Brain Tumors

The median survival rate for patients with glioblastoma, an aggressive type of brain tumor, is approximately 14 months. Approximately 17% of all brain tumors are glioblastomas.
Web Exclusives – April 15, 2015
Tracy Wright

Researchers recently found significantly improved survival rates for a small group of patients with glioblastoma, an aggressive type of brain tumor, by boosting their immune system with the tetanus vaccine before the administration of a dendritic-cell immunotherapy.

The median survival rate for patients with glioblastoma is approximately 14 months. Approximately 17% of all brain tumors are glioblastomas.

The study from researchers at the Duke Cancer Institute included 12 patients with glioblastoma. Overall, 6 patients received a tetanus booster and 6 patients received a placebo shot. The following day, all 12 patients received the dendritic-cell immunotherapy.

Of the patients in the placebo group, 50% lived approximately 18.5 months, which is slightly longer than the average survival rate seen in patients who receive chemotherapy. The survival rates were better in the tetanus group. Among the patients who received the tetanus booster, 3 patients survived an average of 22 months, 1 patient survived 4.8 years, 1 patient survived 5.9 years, and 1 patient is still alive and has had no tumor growth for almost 9 years now.

In dendritic-cell immunotherapy, the patients’ own white blood cells are extracted, “trained” to recognize and attack the tumor cells, and then re-injected back into the patient. This therapy already showed promise by improving the average survival rate of patients from approximately 13 months to 18 months.

Researchers believe that the tetanus shot further increased survival rates by creating an allergic reaction and priming the patient’s immune system to be on the alert for the dendritic-cell vaccine, thus improving the efficacy and the benefit of the vaccine and increasing the patient’s survival.


Recommended For You
COVID-19From Your NavigatorNewsworthy
Coronavirus FAQs for People with Cancer: Interview with Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
By Yvette Florio Lane
COVID-19, the respiratory infection caused by the new coronavirus, is making headlines around the world. Find out what you need to know about this global disease outbreak and how to protect yourself.
FDA Approvals, News & UpdatesNewsworthy
FDA and CDC Investigate Outbreak of Vaping-Related Illness
In the past week, the US Food and Drug Administration (FDA) has released 2 public announcements related to the use of vaping products.
FDA Approvals, News & UpdatesLymphomaNewsworthy
Polivy a New Targeted Immunotherapy Approved for Patients with B-Cell Lymphoma
In June 2019, the FDA approved a new type of immunotherapy called Polivy, for use in combination with other drugs, in patients with previously treated diffuse large B-cell lymphoma (DLBCL), offering new options for patients whose cancer has returned.
Last modified: October 4, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.